Amir Heshmatpour's New Role at NeOnc Technologies
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company dedicated to advancing innovative treatments for central nervous system cancers and disorders, has recently announced a significant leadership change. Amir Heshmatpour, who has been serving as the Executive Chairman, has now been appointed as the President of the company. In this expanded role, he will manage the day-to-day operations while retaining his duties as Executive Chairman, ensuring a seamless transition in leadership.
Strategic Vision for NeOnc
Dr. Thomas Chen, CEO of NeOnc, praised Amir’s appointment as a signal of their commitment to strong leadership during this transformative phase for the company. "Amir’s extensive experience in building robust companies and his deep knowledge of capital markets makes him a vital asset as we continue to advance our clinical programs," stated Dr. Chen.
Background of Amir Heshmatpour
Amir Heshmatpour is no stranger to the business world; he brings over 25 years of high-level executive experience in various domains including business development, operations, finance, and mergers and acquisitions. As the founder, chairman, and managing director of AFH Holdings & Advisory, he has overseen initial public offerings worth over $1.5 billion and played a pivotal role in private funding and M&A transactions exceeding $5 billion.
Previous Accomplishments
Before his current positions, Heshmatpour founded Metrophone Telecommunications in 1994, where he served as Chairman and CEO. Under his guidance, Metrophone successfully completed 17 acquisitions and achieved annual revenues surpassing $100 million over ten years of consecutive growth. His commitment to education and community service is evident through over a decade of service on the board of the UCLA Anderson School of Management and his involvement with the Make-A-Wish Foundation.
A Focus on Clinical Development
Expressing his excitement about stepping into the role of President, Heshmatpour emphasized the importance of this new stage in NeOnc’s journey. He expressed, "Formalizing my day-to-day oversight of Company operations will allow Dr. Chen to concentrate fully on our clinical trials, especially focusing on patient enrollment for our lead drug candidates — NEO212, a TMZ bio-conjugate, and NEO100." Heshmatpour's confidence in the company's capacity to bring significant advantages to patients and shareholders is evident as their promising drug candidates move forward.
About NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is at the forefront of developing and commercializing therapeutics for the central nervous system, tackling the complex issue of overcoming the blood-brain barrier. The company has invested heavily in research and development, utilizing its NEO™ drug development platform. This strategic investment has led to the creation of innovative drug candidates with patent protections extending until 2038.
Among their significant advances are the therapeutics NEO100™ and NEO212™, both currently in Phase II clinical trials and holding FDA Fast-Track and Investigational New Drug status. The company also boasts an exclusive, comprehensive worldwide patent portfolio licensed from the University of Southern California, encompassing both issued patents and pending applications pertinent to NEO100 and NEO212, as well as other products targeted at oncological and neurological challenges.
Contact Information
The leadership at NeOnc remains accessible and ready to engage with potential investors and stakeholders. For inquiries, reach out to:
Patrick Walters
Chief Operations Officer
NeOnc Technologies Holdings, Inc.
Email: info@neonc.com
Investor Relations:
Roger Pondel / Laurie Berman
PondelWilkinson Inc.
(310) 279-5980
Email: rpondel@pondel.com / lberman@pondel.com
Frequently Asked Questions
What recent executive change occurred at NeOnc Technologies?
Amir Heshmatpour has been appointed as President of NeOnc Technologies while remaining the Executive Chairman.
What is the main focus of NeOnc Technologies?
The company is dedicated to developing innovative treatments for central nervous system cancers and disorders.
What are the lead drug candidates of NeOnc?
NeOnc is advancing NEO212 and NEO100 as its leading drug candidates currently in Phase II clinical trials.
How does NeOnc address the blood-brain barrier?
NeOnc's NEO™ drug development platform seeks to develop therapeutics capable of overcoming the challenges associated with the blood-brain barrier.
Who can be contacted for investor relations?
Roger Pondel and Laurie Berman from PondelWilkinson Inc. handle investor relations and can be reached at (310) 279-5980.
